托法替布缓释片联合甲氨蝶呤达标后停用甲氨蝶呤的随机非劣效试验
ORAL Shift 是一项 3b/4 期随机非劣效试验,纳入 533 例经开放标签托法替布缓释片 11 mg 每日一次联合甲氨蝶呤治疗 24 周达到低疾病活动度(CDAI≤10)的类风湿关节炎患者。两组不良事件发生率均为 41%,未发现新的安全性信号。
要点
- 托法替布联合甲氨蝶呤达到低疾病活动度后停用甲氨蝶呤,疾病活动度变化非劣于继续联合治疗。
- 停用甲氨蝶呤组与继续联合组不良事件发生率均为 41%,安全性无意外。
- 研究提示部分患者可考虑在达标后停用甲氨蝶呤,但需个体化评估。
核心结论
- 使用托法替布联合甲氨蝶呤达到低疾病活动度的类风湿关节炎患者,停用甲氨蝶呤未导致疾病活动度显著恶化或意外安全性问题。
研究设计与样本
- ORAL Shift 为 3b/4 期随机、双盲、非劣效试验,在 16 个国家 109 个中心进行。
- 694 例中重度类风湿关节炎且对甲氨蝶呤应答不足的患者进入开放标签期,接受托法替布缓释片 11 mg 每日一次联合甲氨蝶呤治疗 24 周。
- 533 例达到 CDAI≤10 的低疾病活动度患者随机 1:1 接受托法替布联合安慰剂(即掩蔽停用甲氨蝶呤)或继续托法替布联合甲氨蝶呤治疗 24 周。
主要发现
- 托法替布单药组 264 例中 107 例(41%)发生不良事件,继续联合组 266 例中 109 例(41%)发生不良事件。
- 两组各有 5 例因不良事件停药,继续联合组有 2 例死亡,截至 48 周未报告新的安全性发现。
关键数值与推荐
- 低疾病活动度定义:CDAI≤10。
- 主要终点:第 24 周至第 48 周 DAS28-4(ESR) 变化值。
临床怎么用
- 对于托法替布联合甲氨蝶呤治疗达到低疾病活动度的类风湿关节炎患者,可考虑停用甲氨蝶呤,但需结合患者具体情况个体化决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tofacitinib is an oral Janus kinase (JAK) inhibitor used for the treatment of rheumatoid arthritis. We assessed the efficacy and safety of tofacitinib after methotrexate withdrawal in patients who achieved low disease activity (LDA) with tofacitinib in combination with methotrexate. METHODS: ORAL Shift was a phase 3b/4 non-inferiority trial in patients aged at least 18 years with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate done in 109 centres across 16 countries. After 24 weeks of open-label tofacitinib modified-release 11 mg once daily plus methotrexate, patients who achieved LDA (clinical disease activity index [CDAI] ≤10) were randomly assigned 1:1 via an automated web-based response system to receive tofacitinib plus placebo (tofacitinib monotherapy; ie, masked methotrexate withdrawal) or continue tofacitinib plus methotrexate for 24 weeks in a double-blind manner. The primary endpoint was the least squares mean change from week 24 to week 48 in disease activity score in 28 joints with four variables, including erythrocyte sedimentation rate (DAS28-4[ESR]). The primary analysis was done in all patients who received at least one dose of study treatment in both phases, and safety was assessed in all patients who received at least one dose of study treatment since enrolment. Non-inferiority of tofacitinib monotherapy versus tofacitinib plus methotrexate was declared if the upper bound of the 95% CI for the difference in change in DAS28-4(ESR) between treatment groups was less than 0·6. Safety was assessed in both phases. The trial is registered with ClinicalTrials.gov, NCT02831855, and is complete. FINDINGS: Between Sept 1, 2016, and Nov 1, 2017, 694 patients were enrolled in the open-label phase and 623 received study treatment for 24 weeks. 533 achieved CDAI-defined LDA and were randomly assigned into the double-blind phase (267 in the tofacitinib monotherapy group and 266 in the tofacitinib plus methotrexate group). Three participants in the monotherapy group did not start treatment so were not included in the primary analysis. Non-inferiority was demonstrated (difference 0·30 [95% CI 0·12-0·48]). 107 (41%) of 264 patients in the tofacitinib monotherapy group and 109 (41%) of 266 in the tofacitinib plus methotrexate group had adverse events; five patients from each group discontinued because of adverse events; two patients died in the tofacitinib plus methotrexate group. No new safety findings were reported up to 48 weeks. INTERPRETATION: Patients with rheumatoid arthritis who achieve LDA with a combination of tofacitinib plus methotrexate may consider withdrawing methotrexate without significant worsening of disease activity or unexpected safety issues. FUNDING: Pfizer.
引用
- Cohen SB, Pope J, Haraoui B, et al. Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily plus methotrexate (ORAL Shift): a randomised, phase 3b/4, non-inferiority trial. Lancet Rheumatol. 2019. PMID: 38229356. doi:10.1016/S2665-9913(19)30005-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。